insights_auto
Why is NTLA down 2.98%?
Dive Deeperchevron_right
NTLA:NASDAQ
Intellia Therapeutics Inc
$12.37
arrow_downward
-2.98%(-0.38) 1D
$12.40
arrow_upward
+0.24% (+0.030)bedtimeAfter hours
Closed: Oct 6, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NTLA...
Open
$12.50
High
$13.22
Low
$12.04
Mkt. cap
1.67B
Avg. vol.
4.08M
Volume
7.95M
52-wk high
$28.25
52-wk low
$7.95
EPS
-$3.36
Beta
1.80
Shares outstanding
140.13M
No. of employees
377
Open
$12.50
High
$13.22
Low
$12.04
Mkt. cap
1.67B
Avg. vol.
4.08M
Volume
7.95M
52-wk high
$28.25
52-wk low
$7.95
EPS
-$3.36
Beta
1.80
Shares outstanding
140.13M
No. of employees
377
News stories
From web sources and news partners
Kalkine Media
·
5 hours ago
Intellia Therapeutics VP Michael P. Dube Executes Mandatory Sale of 1,864 Shares for Tax Withholding on October 2, 2026
BigGo Finance
·
8 hours ago
Cathie Wood's ARK Invest Rotates $22 Million in Biotech, Extends Intellia Buying Streak to 50 Sessions
Benzinga
·
11 hours ago
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
GuruFocus
·
13 hours ago
NTLA Initiates Coverage On Barclays -- Rating Set to Underweight
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees377
Founded2014
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websiteintelliatx.com